|
 |
Resources
Subarachnoid hemorrhage afflicts an estimated 30,000 people in the US
each year1, and the prognosis for these individuals is poor: about 25%
die and 50% of survivors suffer serious disabilities2.
Timely diagnosis and appropriate treatment can have a significant effect on
neurological outcomes.
We hope that the following curriculum is useful in your efforts to diagnose and treat patients with SAH.
- An overview of SAH, including epidemiology and risk factors
- Diagnosis, including clinical grading scales
- Treatment guidelines
- Efficacy and safety information on Nimotop®(nimodipine) capsules
Download Curriculum PDFs:
To view or print these documents, you must use the Adobe Acrobat Viewer. Acrobat is free and available directly from Adobe's Web site (www.adobe.com) with full installation instructions. You can either view and print these documents or save them to your computer's hard drive to open later. Your method may vary depending on your operating system and browser type.
Sources:
- AHA http://www.americanheart.org/presenter.jhtml?identifier=1192
(Copyright 2005 American Heart Association, Inc.)
- Mayberg MR, Batjer HH, Dacey R et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare
professionals from a special writing group of the Stroke Council, American
Hearth Association. Stroke 1994;25:2315-2328.
|
|
DO NOT ADMINISTER NIMOTOP INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE-THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMOTOP CAPSULES HAVE BEEN INJECTED PARENTERALLY
(See
WARNINGS and DOSAGE AND ADMINISTRATION.) |
| |
- In patients with SAH, Nimotop® controls damage with a low side effect profile.
- Decreased blood pressure is the most common side effect, occurring in 4.4% of patients. Blood pressure should be monitored during therapy.1
- Other side effects occurring at a low frequency of ≥1.0% include headache, nausea, and bradycardia.1
- No clinically significant effects on hematologic factors, renal or hepatic function, or carbohydrate metabolism have been causally associated with oral nimodipine.1
- Nimotop® does not appear to affect anesthetic management.2
|
| |
Sources:
- Nimotop® (nimodipine) Capsules Prescribing
Information December 2005
- Stullken EH, Johnston WE, Prough DS. Implications of nimodipine prophylaxis of cerebral vasospasm on anesthetic management during intracranial aneurysm clipping. J. Neurosurg. 1985; 62:200-205.
|
|
© Bayer HealthCare Pharmaceuticals.
Bayer HealthCare Pharmaceuticals
6 West Belt
Wayne, NJ 07470
The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the US.
|
|
|
